This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
granisetron 10 microg./Kg (n=33, 19 male, mean age 5.5 (+/-3.2)); and granisetron 40 microg./Kg (n=33, 13 male, mean age 4.5 (+/-2.8)).
The sample size of the placebo group was determined by power analysis based on the assumption that the incidence of emesis for the placebo and granisetron groups would be similar to a previous placebo-controlled study of ondansetron in the same patient population.
Study design
Randomized, double-blind controlled study. The duration of the follow-up (after surgery) was 24 hours. The loss to follow-up were not given.
Analysis of effectiveness
The analysis of the clinical study was based on treatment completers only. The primary health outcomes were the incidence and frequency of postoperative emesis and times to discharge readiness.
Effectiveness results
The incidence of postoperative emesis was 35% in the placebo, group, 27% in the 10 microg./Kg granisetron group and 3% in the 40 microg./Kg granisetron group (P<0.05). The emesis during the first 24 hours postoperative was 42%, 33% and 9% inthe placebo, 10 microg./Kg granisetron and 40 microg./Kg granisetron, respectively. The time to discharge readiness was 152 (+/-85) minutes, 129 (+/-56) minutes and 108 (+/-54) minutes in the placebo, 10 microg./Kg granisetron and 40 microg./Kg granisetron, respectively.
Clinical conclusions
Granisetron 40 microg./Kg intravenously was estimated to reduce the incidence, frequency of postoperative emesis and discharge readiness when compared with granisetron 10 microg./Kg and placebo, both in the ambulatory surgery centre and during the first 24 hours.
Modelling
A decision tree was used to divide each study group into nine mutually exclusive subgroups, depending on the incidence of PONV, need for rescue therapy and the side effects of antiemetics.
Measure of benefits used in the economic analysis
No summary benefit measure was used in the analysis and as such the benefits were considered to be the same as the outcome measures.
Direct costs
The antiemetic drug, emesis clean-up, materials, nursing labor, housekeeping labour, and side effects of antiemetic drugs costs were included in the analysis. The quantities were reported separately from the prices. The quantity/cost boundary adopted was the hospital. Discounting was not applied. The price year was not stated.
Statistical analysis of costs
The Mantel-Haenszel test, analysis of variance, Scheffe's test, Kruskall-Wallis test, Fisher's exact and chi-square tests with a Yates' continuity correction were used. P values and mean +/-SD were reported.
